In vivo augmentation of IFN-γ with a rIL-12 human/mouse chimera: Pleiotropic effects against infectious agents in mice and rats

• Published in: Cytokine (Philadelphia, Pa.) Vol. 6; no. 3; pp. 318 - 328
• Main Authors: Gladue, Ronald P., Laquerre, Ann M., Magna, Holly A., Carroll, Laurie A., O'Donnell, Michele, Changelian, Paul S., Franke, Arthur E.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.05.1994
• Subjects: Animals; Antibodies - pharmacology; Cell Line; E. coli; Escherichia coli Infections - immunology; Female; Growth Substances - pharmacology; Growth Substances - therapeutic use; Humans; IFN-γ; IL-12; Interferon-gamma - biosynthesis; Interferon-gamma - blood; Interleukin-12; Interleukins - biosynthesis; Interleukins - pharmacology; Interleukins - therapeutic use; L. monocytogenes; Lipopolysaccharides - toxicity; Listeria monocytogenes - drug effects; Listeria monocytogenes - growth & development; Listeriosis - immunology; Listeriosis - therapy; Liver - drug effects; Liver - microbiology; Lung - drug effects; Lung - microbiology; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Rats; Recombinant Fusion Proteins - biosynthesis; Recombinant Fusion Proteins - pharmacology; Recombinant Fusion Proteins - therapeutic use; Staphylococcal Infections - immunology; Staphylococcal Infections - therapy; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha - biosynthesis; Virus; Virus Diseases - immunology; Virus Diseases - therapy; Virus; IFN-γ; L. monocytogenes; IL-12; E. coli
• ISSN: 1043-4666; 1096-0023
• DOI: 10.1016/1043-4666(94)90029-9

A heterodimer containing the mouse 35 kDa and human 40 kDa subunit of IL-12 was expressed in COS cells (cIL-12). Administration of 25–200 U of the cIL-12-COS supernatant to mice twice daily for 2 days augmented spleen cell IFN-γ production in response to IL-2 and peritoneal macrophage activity (superoxide and nitrites) as compared to animals receiving mock transfected supernatants. cIL-12 also increased levels of IFN-γ in serum but most dramatically following an LPS injection (50-fold over controls). Animals pretreated with cIL-12 suffered enhanced mortality following challenge with the Gram negative organism E. coli but enhanced survival or clearance following infection with the Gram positive organisms L. monocytogenes and S. aureus. Although daily treatment of mice with cIL-12 following an intranasal influenza A infection elevated levels of IFN-γ in the bronchioalveolar lavage fluid three-fold over controls, neither prophylactic or therapeutic treatment with the same dose level decreased viral titres in the lung. In addition, no effect was observed in animals infected with encephalomyocarditis virus or respiratory syncytial virus. Therefore, cIL-12 is a potent in vivo augmentor of IFN-γ production. It has differential effects on infectious disease depending on the invading organism and time of administration; being efficacious for intracellular bacteria but ineffective at the same dose levels against viral diseases.